Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
NVL-520
DRUG
2 trials
Sponsors
Nuvalent Inc.
Conditions
Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tumors
Non Small Cell Lung Cancer
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Phase 1
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
Recruiting
CTIS2024-511793-71-00
Nuvalent Inc.
Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tumors
Start: 2022-02-28
Target: 283
Updated: 2026-01-26
Unknown Phase
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
NCT06797362
Nuvalent Inc.
Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Updated: 2026-08-25